Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 24;9(1):bio047662. doi: 10.1242/bio.047662

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 4. — ERBB2-MT group has an elevated proportion of (S+G2+M) stages and the ERBB2-MT tumor has a higher p-AKT level. (A) In cycle distribution, the ERBB2-MT group showed an elevated proportion of (S+G2+M) stages compared with ERBB2-WT when exposed to lapatinib (t=14.97, P<0.05). (B) Under lapatinib+perifosine exposure, the G2+S+M proportion was significantly decreased in the ERBB2 overexpressed groups compared with NC, while no difference was found between WT and MT (t=0.25, P>0.05). (C) Immunohistochemistry staining of tumor sections from two groups of ERBB2+ BC patients. Both groups of patients had a clear positive expression of ERBB2 (and p-ERBB2), while the mutant group exhibited a dramatically higher expression level of p-AKT.